Trial Profile
Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy
Status:
Discontinued
Phase of Trial:
Phase 0
Latest Information Update: 16 Jun 2022
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer
- Focus Pharmacodynamics
- 07 Dec 2021 Status changed from suspended to discontinued, because it was decided that due to lack of accrual on the trial, and low potential for accruing overthe near future, the trial will be shut down.
- 05 Mar 2021 Status changed from recruiting to suspended as it was decided that due to lack of accrual on the trial, and low potential for accruing over the near future, the trial will be shut down.
- 10 Jun 2019 Planned End Date changed from 20 Sep 2019 to 20 Nov 2021.